Pharmaceuticals & Therapeutics

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

With its acquisition of Lantheus' SPECT business, SHINE Technologies is creating a vertically integrated powerhouse to end isotope shortages.

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

Neovii Pharmaceuticals names Frédéric Prince its next CEO, bringing deep oncology and gene therapy experience from Roche to steer its next growth phase.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

Branded Legacy just wiped out $1M in legacy debt. The move is part of a radical overhaul by new management aimed at rebuilding investor confidence.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

For the 13th consecutive year, Karmanos Cancer Institute is named a top US hospital, a distinction driven by patient safety and women's care preferences.

As pharma moves beyond small molecules, a new integrated platform helps developers navigate the challenges of PROTACs, peptides, and antibody drugs.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.